Abstract
The high failure rate of experimental medicines in clinical trials accentuates inefficiencies of current drug discovery processes caused by a lack of tools for translating the information exchange between protein and organ system networks. Recently, we reported that biological activity spectra (biospectra), derived from in vitro protein binding assays, provide a mechanism for assessing a molecule's capacity to modulate the function of protein-network components. Herein we describe the translation of adverse effect data derived from 1,045 prescription drug labels into effect spectra and show their utility for diagnosing drug-induced effects of medicines. In addition, notwithstanding the limitation imposed by the quality of drug label information, we show that biospectrum analysis, in concert with effect spectrum analysis, provides an alignment between preclinical and clinical drug-induced effects. The identification of this alignment provides a mechanism for forecasting clinical effect profiles of medicines.
Similar content being viewed by others
References
Sole, R.V., Pastor-Satorras, R., Smith, E. & Kepler, T.B. A model of large-scale proteome evolution. Preprint at http://xxx.lanl.gov/cond-mat/0207311 (2002).
Tyers, M. & Mann, M. From genomics to proteomics. Nature 422, 193–197 (2003).
Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C. & Liotta, L.A. Clinical proteomics:translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1, 683–695 (2002).
Dimpfel, W. Preclinical data base of pharmaco-specific EEG fingerprints (Tele-Stereo-EEG). Eur. J. Med. Res. 8, 199–207 (2003).
Zajchowski, D.A. et al. Identification of selective estrogen receptor modulators by their gene expression fingerprints. J. Biol. Chem. 275, 15885–15894 (2000).
Shi, L.M. et al. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol. Pharmacol. 53, 241–251 (1998).
Pellegrini, M. Defining interacting partners for drug discovery. Expert Opin. Ther. Targets 7, 287–297 (2003).
Cunningham, M.L., Bogdanffy, M.S., Zacharewski, T.R. & Hines, R.N. Workshop overview: Use of genomic data in risk assessment. Toxicol. Sci. 73, 209–215 (2003).
Padrini, R. et al. Pharmacogenetics. N. Engl. J. Med. 348, 2041–2043 (2003).
Mathew, R.J., Weinman, M.L., Thapar, R., Reck, J.J. & Claghorn, J.L. Somatic symptoms in depression and antidepressants. J. Clin. Psychiatry 44, 10–12 (1983).
Hamilton, L.W. & Timmons, C.R. Sex differences in response to taste and postingestive consequences of sugar solutions. Physiol. Behav. 17, 221–225 (1976).
Antkowiak, B. How do general anaesthetics work? Naturwissenschaften 88, 201–213 (2001).
Steiner, S. & Anderson, N.L. Expression profiling in toxicology-potentials and limitations. Toxicol. Lett. 112–113, 467–471 (2000).
Blower, P.E. et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J. 2, 259–271 (2002).
Fliri, A.F., Loging, W.T., Thadeio, P.F. & Volkmann, R.A. Biological spectra analysis: linking biological activity profiles to molecular structure. Proc. Natl. Acad. Sci. USA 102, 261–266 (2005).
Fliri, A.F., Loging, W.T., Thadeio, P.F. & Volkmann, R.A. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. J. Med. Chem. 48, 6918–6925 (2005).
Hamadeh, H.K., et al. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67, 232–240 (2002).
Park, D. et al. Comparative interactomics analysis of protein family interaction networks using PSIMAP (protein structural interactome map). Bioinformatics 21, 3234–3240 (2005).
Krejsa, C.M. et al. Predicting ADME properties and side effects: The BioPrint approach. Curr. Opin. Drug Discov. Devel. 6, 470–480 (2003).
Food and Drug Administration. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms (3rd edn.) (Food and Drug Administration, Center for Drugs and Biologics, Division of Drug and Biological Products Experience, Rockville, Maryland, 1989).
Gao, H., Williams, C., Labute, P. & Bajorath, J. Binary quantitative structure-activity relationship (QSAR) analysis of estrogen receptor ligands. J. Chem. Inf. Comput. Sci. 39, 164–168 (1999).
Ward, J.H. Hierarchical grouping to optimize an objective function. J. Am. Stat. Assoc. 58, 236–244 (1963).
German, E.J., Wood, D. & Hurst, M.A. Ocular effects of antimuscarinic compounds: Is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? J. Ocul. Pharmacol. Ther. 15, 257–269 (1999).
Itil, T.M. The discovery of antidepressant drugs by computer-analyzed human cerebral bio-electrical potentials (CEEG). Prog. Neurobiol. 20, 185–249 (1983).
Sanger, D.J. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18 (Suppl.) 9–16 (2004).
Hindmarch, I. Myths, medicine and the media. Hum Psychopharmacol. Clin. Exp. 14, 223–224 (1999).
Becker, R.A., Chambers, J.M. & Wilks, A.R. The New S Language: a Programming Environment for Data Analysis and Graphics (Wadsworth & Brooks/Cole Advanced Books & Software, Monterey, California, 1988.
Mardia, K.V., Kent, J.T. & Bibby, J.M. Multivariate analysis. Academic Press, (1979).
Labute, P., Nilar, S. & Williams, C. A probabilistic approach to high throughput drug discovery. Comb. Chem. High Throughput Screen. 5, 135–145 (2002).
Acknowledgements
The authors would like to thank D.M. Potter for useful discussions.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
The experimental design for investigating the information exchange between drug-induced protein network perturbations to drug-induced organ systems perturbations. (PDF 148 kb)
Supplementary Fig. 2
Positions of ninety-two protein assays in the mammalian proteome network. (PDF 3113 kb)
Supplementary Fig. 3
Sedative-hypnotic cluster. (PDF 718 kb)
Supplementary Fig. 4
Side effect distances compared to BioSpectra distances. (PDF 228 kb)
Supplementary Table 1
List of ninety-two assays. (PDF 50 kb)
Supplementary Table 2
List of 872 medicines. (PDF 48 kb)
Supplementary Table 3
ADRS. (PDF 42 kb)
Rights and permissions
About this article
Cite this article
Fliri, A., Loging, W., Thadeio, P. et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol 1, 389–397 (2005). https://doi.org/10.1038/nchembio747
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio747
- Springer Nature America, Inc.
This article is cited by
-
RETRACTED ARTICLE: Analysis and Prediction of Adverse Reaction of Drugs with Machine Learning Models for Tracking the Severity
Arabian Journal for Science and Engineering (2023)
-
Recommender systems in the healthcare domain: state-of-the-art and research issues
Journal of Intelligent Information Systems (2021)
-
Predicting the frequencies of drug side effects
Nature Communications (2020)
-
Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
BMC Medical Informatics and Decision Making (2019)
-
Discovering Links Between Side Effects and Drugs Using a Diffusion Based Method
Scientific Reports (2019)